公开(公告)号：NZ501166A

公开(公告)日：2001-12-21

申请号：NZ50116698

申请日：1998-07-27

Applicant: ABBOTT LAB

Inventor： HOLMS JAMES H ,  STEINMAN DOUGLAS ,  XU LIANGHONG ,  CURTIN MICHAEL L ,  FLORJANCIC ALAN S ,  GONG JIANCHUN ,  HEYMAN H ROBERT ,  MICHAELIDES MICHAEL R ,  WADA CAROL K ,  DAVIDSEN STEVEN K ,  DELLARIA JOSEPH F ,  GIESER JAMIE ,  GUO YAN

IPC: C07D233/74 ,  A61K31/275 ,  A61K31/351 ,  A61K31/352 ,  A61K31/4035 ,  A61K31/4166 ,  A61K31/4178 ,  A61K31/421 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/4465 ,  A61K31/45 ,  A61K31/454 ,  A61K31/50 ,  A61P1/02 ,  A61P1/04 ,  A61P19/02 ,  A61P19/10 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07C259/06 ,  C07C311/05 ,  C07C311/18 ,  C07C317/28 ,  C07C317/40 ,  C07C323/47 ,  C07C323/62 ,  C07D207/40 ,  C07D207/404 ,  C07D207/416 ,  C07D209/48 ,  C07D211/88 ,  C07D213/68 ,  C07D233/76 ,  C07D233/78 ,  C07D237/14 ,  C07D263/44 ,  C07D275/04 ,  C07D275/06 ,  C07D309/14 ,  C07D311/18 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  A61K31/165 ,  A61K31/277 ,  A61K31/425 ,  A61K31/18 ,  A61K31/4015 ,  A61K31/42 ,  A61K31/44

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof, wherein: A is H; n is zero; R1 and R3 are independently H or alkyl; R2 and R4 are independently H; alkyl; alkenyl; alkoxyalkyl; alkoxycarbonylalkyl; haloalkyl; hydroxyalkyl; (alkylene)-S(O)p-alkyl; phenyl; phenylalkoxyalkyl; phenylalkyl; phenoxyalkyl; -(alkylene)-N(R5)S02-phenyl; (heterocycle)oxyalkyl; -(alkylene)-S(O)p-heterocycle; -(alkylene)-heterocycle; or -(alkylene)-NR6R7 or R1 and R2, taken together with the carbon atom to which they are attached form a ring selected from spiroalkyl of 3 to 8 carbon atoms and tetrahydropyranyl; or R3 and R4, taken together with the carbon atom to which they are attached, form a spiroalkyl group of 3 to 8 carbon atoms; or R1 and R3 taken together with the carbon atoms to which they are attached are a 5, 6, or 7-membered carbocyclic ring; X is -0-; -NR5S02-; -S(O)p-; or -C(O)-; wherein each group is drawn with its left-hand end being the end which attaches to the alkylene group and its right-hand end being the end which attaches to Ar1; Ar1 is optionally substituted phenyl; Y is a covalent bond, -O-, alkylene, piperidinyl, alkenylene of two carbon atoms, alkynylene of two carbon atoms, -S(0)p- or -C(O)-; and Ar2 is an optionally substituted aryl group selected from the group consisting of phenyl; pyridyl; pyrazinyl; pyridazinyl; furyl; thienyl; isoxazolyl; oxazolyl; thiazolyl and isothiazolyl; All other variables are as defined in the specification. A pharmaceutical composition comprising the compound of formula (I) and a pharmaceutically acceptable carrier is also described. The compound of formula (I) is used for inhibiting matrix metalloproteinases in mammals.